BioPharma-Synergy (23rd -25th February 2021)

The event is designed for the BD&Licensing pharma professionals focusing on BioSimilars, BioBetter & BioInnovative products. With the audience coming from Europe, LATAM, APAC, MENA & North America – BioPharma-Synergy invites dynamic pharma companies for three days of business partnering meetings and content-driven programme.

Discussions and presentations

The 2021 content-driven programme will focus on successful commercial strategies, pricing consideration, facilitating partnering across Geos between producers and buyers. Among the topics:

Global Biosimilars/Biobetter outlook; key players and their market access strategies

Regulatory approvals, tenders and pricing trends in Europe

Opportunities and trends in biosimilars by region: APAC, MENA, CIS, LATAM

Strategic considerations for biosimilar commercialisation – manufacturers’ point of view

In-licensing strategies in Europe and beyond

Early speaker confirmations include:

o Jamie Unwin, VP & Head, Global Business Intelligence & Analytics, Biocon Biologics

o Jean-Baptiste Duval, Head of International Operations Shanghai Henlius Biotech

o Jayapala Reddy, Associate Vice-President/Global Head, Hetero Biopharma

o Philippe Gautron, Senior Director of Global Business Development own brands, DKSH

o Eduardo Cioppi, Regional Director – Latin America, mAbxience

o Stephani Saverio, Senior Director of Business Development, Knight Therapeutics

o Xiaoli Hu, Head of Business Development, Xbrane Biopharma AB

o Pavan Handa, Executive Vice President and Chief Business Officer, Kashiv Pharm

o Thiago Mares Guia, Scientific & Business Executive Director, Bionovis

o Carlos Berrade, Licensing & Business Development Director, Strategy and Development Area, Kern Pharma

See what speakers say about the event

Watch the online discussion that took place in July 2020: “Global Biosimilars Landscape and Opportunities”